Penumbra, Inc. (PEN)
Makes devices that remove blood clots from arteries and veins during emergency procedures.
$320.70+0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+32.0%
The outlook
Penumbra trades at $320.70, sitting well above its 50- and 200-day moving averages and about 70% of the way up its 52-week range. Analysts lean toward Hold with an average rating of 2.7/5, and their consensus price target sits roughly 13% above the current price. The stock carries a high trailing P/E of 73.7, reflecting premium valuation relative to current earnings.
What’s behind the score
Analyst consensusHold — 2.7 avg of 12 analysts
Price trendAbove its 50- & 200-day averages
52-week range70% of the way from its 52-week low to high
Price targetAvg target +13% vs current price
Analyst price target
~12-month · 12 analysts$361.58average target+12.7% vs now
Now $320.70
Low $320.00High $374.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$12.61B
52-wk high
$362.41
52-wk low
$221.26
50-day avg
$319.44
200-day avg
$314.39
Trailing P/E
73.7